Human Immunoglobulin G
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
- Human Immunoglobulin G
- Human Immunoglobulin G: From No Locally Approved Indication to Severe Nonproliferative Diabetic Retinopathy (Predicted)
Human Immunoglobulin G: From No Locally Approved Indication to Severe Nonproliferative Diabetic Retinopathy (Predicted)
One-Sentence Summary
Human Immunoglobulin G (DrugBank DB00028) is not currently marketed in this jurisdiction, and no approved indication is on file. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but this direction is currently supported by 0 clinical trials and only 1 publication, which is a biomarker-correlation study rather than treatment evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — drug is not marketed locally and no license/indication record exists |
| Predicted New Indication | Severe Nonproliferative Diabetic Retinopathy |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for this drug is currently unavailable (data gap). No original indication is on file locally either, so the usual comparison between an established indication and the predicted new one cannot be made here.
The only literature identified for this candidate (PMID 40204274) investigated serum IgG Fc N-glycosylation patterns as a diagnostic biomarker to distinguish nonproliferative from proliferative diabetic retinopathy — it does not test immunoglobulin G as a therapeutic intervention. The mechanistic link is therefore correlational (IgG glycosylation changes co-occur with disease severity), not causal or interventional, and it remains unclear whether altered IgG glycosylation is a consequence of the disease or a contributor to it.
Because both the original-indication context and the MOA are missing, and the sole supporting publication is an observational biomarker study, the biological rationale for repurposing into this indication is currently weak and should be treated as a model-generated hypothesis rather than a mechanistically grounded prediction.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40204274 | 2025 | Observational/Biomarker | Molecular & Cellular Proteomics | Serum disease-specific IgG Fc N-glycosylation profiled by mass spectrometry in 160 patients (47 non-DR, 51 NPDR, 62 PDR) as a potential diagnostic biomarker distinguishing nonproliferative from proliferative diabetic retinopathy; not a treatment study. |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence is limited to a single observational biomarker study with no supporting clinical trials, and both the drug’s mechanism of action and local regulatory/indication history are unavailable — the mechanistic link to severe nonproliferative diabetic retinopathy is correlational, not interventional.
To proceed, the following is needed:
- Mechanism of action (MOA) data from DrugBank or equivalent source (data gap DG002)
- Local product label / warnings and contraindications (data gap DG001, currently blocking)
- An interventional (not purely observational) study testing immunoglobulin G’s effect on diabetic retinopathy progression or severity
- Clarification of whether IgG Fc glycosylation is causally implicated in retinopathy pathogenesis, versus being a downstream marker of disease severity
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.